We reported second quarter financial results for 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth of the company.
We announced recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. This program promotes and supports innovative research on Tumor Treating Fields through research grants and career development awards totaling more than $2 million.
The FDA has approved our investigational device exemption application to initiate the KEYNOTE-B36 trial evaluating TTFields together with pembrolizumab in NSCLC, conducted in collaboration with MSD. We also announced the formation of a scientific steering committee.
We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 1,000 employees and operations in the U.S., Europe and Asia. With more than 20 years of research and many significant milestones, we believe we are only beginning.